Market Cap | 75.01M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -38.37M | Forward P/E | -3.17 | EPS next Y | - | 50D Avg Chg | 3.00% |
Sales | 3.92M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 11.00% |
Dividend | N/A | Price/Book | 2.30 | EPS next 5Y | - | 52W High Chg | -25.00% |
Recommedations | 2.00 | Quick Ratio | 0.08 | Shares Outstanding | 37.82M | 52W Low Chg | 94.00% |
Insider Own | 52.30% | ROA | -70.09% | Shares Float | 17.85M | Beta | 0.78 |
Inst Own | 3.21% | ROE | -344.32% | Shares Shorted/Prior | 12.80K/11.74K | Price | 2.09 |
Gross Margin | -102.67% | Profit Margin | - | Avg. Volume | 19,456 | Target Price | 3.00 |
Oper. Margin | -2,235.75% | Earnings Date | - | Volume | 5,044 | Change | 2.45% |
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Rhode Peter | See Remarks See Remarks | Dec 11 | Option | 0.14 | 14,000 | 1,960 | 77,500 | 12/11/23 |
Flowers Lee | SVP of Business Deve.. SVP of Business Development | Dec 08 | Option | 0.14 | 7,501 | 1,050 | 118,809 | 12/11/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Oct 19 | Option | 0.14 | 47,249 | 6,615 | 621,195 | 10/23/23 |
Wong Hing C | Chief Executive Offi.. Chief Executive Officer | Sep 14 | Buy | 2.0782 | 1,800 | 3,741 | 15,314,868 | 09/18/23 |
Winer Gary M | Director Director | Sep 13 | Buy | 2.05 | 1,587 | 3,253 | 17,000 | 09/15/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Sep 13 | Buy | 2.098 | 5,000 | 10,490 | 573,946 | 09/15/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Sep 11 | Buy | 2.07 | 10,000 | 20,700 | 568,946 | 09/13/23 |
Winer Gary M | Director Director | Sep 08 | Buy | 2 | 600 | 1,200 | 15,413 | 09/12/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Sep 07 | Buy | 1.99 | 10,000 | 19,900 | 558,946 | 09/08/23 |
Winer Gary M | Director Director | Sep 05 | Buy | 1.85 | 463 | 857 | 14,813 | 09/07/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Sep 06 | Buy | 1.9498 | 5,000 | 9,749 | 548,946 | 09/07/23 |
Flowers Lee | SVP of Business Deve.. SVP of Business Development | Jun 08 | Buy | 2.16 | 10,000 | 21,600 | 111,308 | 06/09/23 |
Flowers Lee | SVP of Business Deve.. SVP of Business Development | Jun 08 | Option | 0.14 | 5,356 | 750 | 101,308 | 06/09/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Jun 09 | Buy | 2.0643 | 20,000 | 41,286 | 543,946 | 06/09/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Jun 07 | Buy | 2.12 | 24,696 | 52,356 | 523,946 | 06/08/23 |
Wong Hing C | Chief Executive Offi.. Chief Executive Officer | Jun 01 | Buy | 1.58 | 1,600 | 2,528 | 15,313,068 | 06/02/23 |
Wong Hing C | Chief Executive Offi.. Chief Executive Officer | May 30 | Buy | 1.55 | 5,000 | 7,750 | 15,311,468 | 06/01/23 |
Winer Gary M | Director Director | May 30 | Buy | 1.51 | 1,350 | 2,038 | 14,350 | 06/01/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | May 25 | Buy | 1.64 | 40,000 | 65,600 | 460,188 | 05/31/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | May 22 | Buy | 1.57 | 58,486 | 91,823 | 420,188 | 05/24/23 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Sep 12 | Buy | 2.61 | 30,000 | 78,300 | 312,952 | 09/14/22 |
Wong Hing C | Chief Executive Offi.. Chief Executive Officer | Sep 02 | Buy | 2.57 | 10,000 | 25,700 | 15,296,468 | 09/07/22 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Aug 26 | Buy | 2.55 | 20,000 | 51,000 | 265,752 | 08/30/22 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Aug 24 | Buy | 2.55 | 90,300 | 230,265 | 245,752 | 08/26/22 |
Byam Rebecca | Chief Financial Offi.. Chief Financial Officer | Jun 13 | Buy | 2.27 | 66,452 | 150,846 | 155,452 | 06/15/22 |
Wong Hing C | Chief Executive Offi.. Chief Executive Officer | Jun 10 | Buy | 2.188 | 1,520 | 3,326 | 15,286,468 | 06/13/22 |
Winer Gary M | Director Director | Jun 08 | Buy | 2.2 | 3,500 | 7,700 | 13,000 | 06/10/22 |
Wong Hing C | Chief Executive Offi.. Chief Executive Officer | Jun 07 | Buy | 2.28 | 3,000 | 6,840 | 15,284,948 | 06/09/22 |
Greene Rick S. | Director Director | Jun 02 | Buy | 2.0918 | 4,800 | 10,041 | 8,411 | 06/06/22 |
Rhode Peter | See Remarks See Remarks | Jan 14 | Option | 0.18 | 1,715 | 309 | 48,500 | 01/19/22 |